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RegistriesAbstract Introduction: Smoking prevalence has been declining in men all over Europe, while
the trend varies in European regions among women. To study the impact of past smoking
prevalence, we present a comprehensive overview of the most recent trends in incidence, dur-
ing 1988–2010, in 26 countries, of four of the major cancers in the respiratory and upper gas-
tro-intestinal tract associated with tobacco smoking.
Methods: Data from 47 population-based cancer registries for lung, laryngeal, oral cavity and
pharyngeal, and oesophageal cancer cases were obtained from the newly developed data
repository within the European Cancer Observatory (http://eco.iarc.fr/). Truncated age-
standardised incidence rates (35–74 years) by calendar year, average annual percentage change
in incidence over 1998–2007 were calculated. Smoking prevalence in selected countries was
extracted from the Organisation for Economic Co-operation and Development and the World
Health Organization databases.
Results: There remained great but changing variation in the incidence rates of tobacco-related
cancers by European region. Generally, the high rates among men have been declining, while
the lower rates among women are increasing, resulting in convergence of the rates. Female lungs, 69008
Table 1
Populations studied by country (N = 26
covered by the 47 national or regional s
Region Countries Years
Central & eastern Europe
Belarus 1988–
Bulgaria 1993–
Czech Republic 1988–
Polanda 1988–
Russian
Federation
1993–
Slovakia 1988–
Northern Europe
Denmark 1988–
Estonia 1988–
Finland 1988–
Iceland 1988–
Ireland 1994–
Latvia 1988–
Lithuania 1988–
Norway 1988–
Sweden 1988–
United Kingdoma 1988–
Southern Europe
Croatia 1988–
Italya 1988–
Malta 1992–
Slovenia 1988–
Spaina 1988–
Western Europe
Austria 1990–
Francea 1988–
Germanya 1998–
Switzerlanda 1988–
The Netherlands 1989–
Total
a Regional registries: France (Doubs,
North Rhine-Westphalia, Saarland); Po
Murcia, Navarra, Tarragona); Switzerla
b Population data from 2005.
J. Lortet-Tieulent et al. / European Journal of Cancer 51 (2015) 1144–1163 1145cancer rates were above male rates in Denmark, Iceland and Sweden (35–64 years). In lung and
laryngeal cancers, where smoking is the main risk factor, rates were highest in central and east-
ern Europe, southern Europe and the Baltic countries. Despite a lowering of female smoking
prevalence, female incidence rates of lung, laryngeal and oral cavity cancers increased in most
parts of Europe, but were stable in the Baltic countries. Mixed trends emerged in oesophageal
cancer, probably explained by differing risk factors for the two main histological subtypes.
Conclusions: This data repository offers the opportunity to show the variety of incidence trends
by sex among European countries. The diverse patterns of trends reﬂect varied exposure to risk
factors. Given the heavy cancer burden attributed to tobacco and the fact that tobacco use is
entirely preventable, tobacco control remains a top priority in Europe. Prevention efforts
should be intensiﬁed in central and eastern Europe, southern Europe and the Baltic countries.
 2013 Elsevier Ltd. All rights reserved.1. Introduction
Tobacco was introduced into Europe by Spanish
explorers returning from the Americas in the late ﬁf-
teenth century. By the late nineteenth century, tobacco), study period, population covere
tudied registries.
2007 Population in the stu
(thousands)
2007 9,702
2008 7,660
2008 10,323
2008 2,042
2008 142,115
2007 5,398
2010 5,461
2007 1,341
2010 5,289
2010 311
2007 4,339
2007 2,276
2007 3,376
2009 4,708
2009 9,148
2007 56,236
2007 4,436
2007 4,359
2009 409
2007 2,019
2005 3,502b
2009 8,301
2009 4,388
2007 13,888
2008 968
2008 16,382
328,376
Herault, Isere, Haut-Rhin, Somm
land (Kielce, Cracow); Italy (Mo
nd (Geneva, St Gall-Appenzell), Uwas being widely used by men in Europe [1], ﬁrst in
the forms of pipe-, cigar-smoking and snuﬀ-taking.
Then, after mass production became possible at the
end of the nineteenth century, cigarettes, strongly pro-
moted by advertising and marketing eﬀorts, becamed by the registration area and proportion of the national population
died registries Proportion of the national population covered
(%)
100
100
100
5.2
100
100
100
100
100
100
100
100
100
100
100
88.3
100
6.9
100
100
7.7
100
6.8
16.1
12.3
100
e, Tarn); Germany (Brandenburg, Hamburg, Saxony, Mecklenburg,
dena, Parma, Ragusa, Romagna, Torino, Varese); Spain (Granada,
nited Kingdom (England and Scotland).
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Fig. 1. Trends in lung cancer age-standardised (European) incidence in men aged 35–74 by country and region, from 1988 to the most recent year
available (2005–2010). § regional registries.
1146 J. Lortet-Tieulent et al. / European Journal of Cancer 51 (2015) 1144–1163the norm for tobacco consumption. From the 1930s,
together with the forces of emancipation, women began
adopting the habit on a large scale, ﬁrst in North Amer-
ica and in northern and western Europe, until the 1970s.
By the 1960s, the smoking prevalence in men was at least
70% in Denmark, the United Kingdom (UK) and
Belgium and 90% in the Netherlands, and around 30%
in women [2]. Thereafter, the proportion of smokers rap-
idly decreased in men in these parts of Europe, falling to
around 40–50% by 1988. In contrast, in women, the prev-
alence rose gradually over time, but remained lower than
in men. In southern Europe, the tobacco epidemic lagged
behind that in northern and western Europe, especially in
women. In Russia, a small but signiﬁcant rise in the prev-
alence of tobacco smoking among men was reported,from 57% in 1992 to 63% in 2003, whereas rates among
women more than doubled from 7% to 15% in the same
period [3]. From the mid-1990s until 2002, the prevalence
of smoking among men in Estonia, Latvia and Lithuania
was around 50% (compared to 29% in Finland), and ran-
ged between 10% and 20% among women. Smoking
increased among Lithuanian women from 6% in 1994 to
13% in 2002, but decreased among Estonian men and
women [4]. Mass cigarette use followed the economic
development in Europe: ﬁrstly in northern and western
Europe, secondly in southern Europe, thirdly in central
and eastern Europe.
Cigarette smoking is a causal agent for cancers of the
oral cavity, oropharynx, nasopharynx, hypopharynx,
oesophagus, stomach, colorectum, liver, pancreas, nasal
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Fig. 2a. Average annual percentage change (AAPC) between 1998 and
2007 (except 1996–2005 for Spain) and age-standardised (European)
incidence rates (ASR) of the most recent year (2005–2010) of lung
cancer in men aged 35 to 64. Dots indicate statistically signiﬁcant
AAPC (p 6 0.05); triangles indicate non-signiﬁcant AAPC AUS –
Austria; BEL – Belarus; BUL – Bulgaria; CRO – Croatia; CZR –
Czech Republic; DEN – Denmark; EST – Estonia; FIN – Finland;
FRA§ – France (regional registries); GER§ – Germany (regional
registries); ICE – Iceland; IRE – Ireland; ITA§ – Italy (regional
registries); LAT – Latvia; LIT – Lithuania; MAL – Malta; NOR –
Norway; POL§ - Poland (regional registries); RUS – Russian Feder-
ation; SLK – Slovakia; SLN – Slovenia; SPA§ – Spain (regional
registries); SWE – Sweden; SWI§ – Switzerland (regional registries);
NL – The Netherlands; UK§ – United Kingdom (regional registries).
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Fig. 2b. Average annual percentage change (AAPC) between 1998 and
2007 (except 1996–2005 for Spain) and age-standardised (European)
incidence rates (ASR) of the most recent year of lung cancer in men
aged 65 to 74. Dots indicate statistically signiﬁcant AAPC (p 6 0.05);
triangles indicate non-signiﬁcant AAPC. § Regional registries.
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ovary, urinary bladder, kidney, ureter and bone marrow
(myeloid leukaemia). Second-hand tobacco smoke and
smokeless tobacco also induce cancer [5]. The European
Prospective Investigation into Cancer and Nutrition
Study (EPIC) calculated that among the 19 above-men-
tioned tobacco-related cancer cases, 35% of them were
attributable to cigarette smoking (42% in men and
23% in women) [6]. In 2012 in Europe (40 countries),
there were an estimated almost 600,000 new cases of:
lung (410,000), oral cavity and pharyngeal (100,000),
oesophageal (46,000) and laryngeal cancer (40,000) [7],
the cancers for which the fraction attributable to smok-
ing is highest (with lower urinary tract). For each of
these sites, men represented 71% to 90% of the patients.
Using high-quality population-based cancer registra-
tion data, this study aims to identify patterns in the inci-
dence of major tobacco-related cancers (lung, laryngeal,
oral cavity and oesophageal cancer), between 1988 and
2010, especially contrasting trends in men and women.
We analysed data from 47 cancer registries covering
328 million inhabitants, representing 26 European coun-
tries, using age-standardised rates and average annual
percentage change and compared smoking prevalence
to lung cancer incidence.2. Methods
Incidence data by year, 5-year age group, cancer and
sex and corresponding population ﬁgures were obtained
from the EUREG database, part of the European Can-
cer Observatory (ECO) website (http://eco.iarc.fr) [8]
hosted by the International Agency for Research on
Cancer (IARC). The ECO website was developed within
the framework of the EUROCOURSE project to enable
the rapid exploration of geographical patterns and tem-
poral trends of incidence, mortality and survival
observed in European population-based cancer regis-
tries. The cancer registries were invited to submit their
data, in 2010, through a web portal. As of mid-2013,
130 of the 200 European registries had contributed.
To ensure a high level of data quality and data com-
parability for this study, cancer registries from the
EUREG database were only included in this study if
they had been published in Volume IX of Cancer Inci-
dence in Five Continents (CI5) [9] and had available
annual incidence data for at least 10 consecutive years
from 1998 onwards. The rigorous process of data qual-
ity assurance in CI5 is described elsewhere [9].
To assess recent trends, the period of analysis was
restricted to 1988 and thereafter.
The Malta National Cancer Registry submitted data
to the EUREG database for 1994–2009. To expand the
length of the study period additional data for 1992–1993
were extracted from CI5plus [10], which contains annual
incidence for selected cancer registries published in CI5
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Fig. 3. Trends in lung cancer age-standardised (European) incidence in women aged 35–74 by country and region, from 1988 to the most recent
year available (2005–2010). § Regional registries.
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(2008–2009), Danish and Finnish (2008–2010) data were
extracted from NORDCAN [11], a database maintained
by the Association of the Nordic Cancer Registries.
Lastly, Russian data were available through the Minis-
try of Health and Social Development [12], as data from
the St Petersburg registry published in CI5 were only
available for 1992–1997. Russia is a populous European
country whose cancer trends serve as references for the
other central and eastern European countries. Russian
national data presented a high percentage of microscop-
ically veriﬁed records (>85%), acceptable for CI5 selec-
tion standards.
Finally, population-based registries from 26 Euro-
pean countries (Table 1) were included in this studyand grouped into four regions, according to the United
Nations classiﬁcation [13]. Of the 26 countries, 19 had
national data. For the remaining seven countries, data
from regional registries were aggregated to obtain an
estimate of the (unknown) national incidence (see foot-
note of Table 1 for the list of the regional registries).
When combining regional registries, we aimed to maxi-
mise the population coverage of the country by selecting
as many registries as possible that had a common regis-
tration period and which met the inclusion criteria.
Unfortunately, in Italy, due to the selection process,
only registries from the northern part of the country
were eligible.
Of the 19 cancer sites associated with tobacco, lung
and larynx were estimated to have the highest population
AUS
BEL
BUL
CRO
CZR
DEN
EST
FIN
FRA§
GER§
ICE
IRE
ITA§
LAT
LIT
MAL
NOR
POL§
RUS
SLK
SLN
SPA§
SWE
SWI§
NL
UK§
−2
−1
0
1
2
3
4
5
6
7
8
9
10
An
nu
al
 p
er
ce
nt
ag
e 
ch
an
ge
 (%
) f
or
 3
5−
64
 y
ea
rs
−o
ld
, 1
99
8−
20
07
0 10 20 30 40 50 60 70
Age−standardised (European) incidence rate per 100,000 in most recent year
Fig. 4a. Average annual percentage change (AAPC) between 1998 and
2007 (except 1996–2005 for Spain) and age-standardised (European)
incidence rates (ASR) of the most recent year of lung cancer in women
aged 35 to 64. Dots indicate statistically signiﬁcant AAPC (p 6 0.05);
triangles indicate non-signiﬁcant AAPC. Colours indicate European
regions: Central and eastern (blue), northern (green), southern (red)
and western (brown). § Regional registries.
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Fig. 4b. Average annual percentage change (AAPC) between 1998 and
2007 (except 1996–2005 for Spain) and age-standardised (European)
incidence rates (ASR) of the most recent year of lung cancer in women
aged 65 to 74. Dots indicate statistically signiﬁcant AAPC (p 6 0.05);
triangles indicate non-signiﬁcant AAPC. Colours indicate European
regions: Central and eastern (blue), northern (green), southern (red)
and western (brown). § Regional registries.
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82% and 84% respectively, in the EPIC study [6].Therefore, trends in both lung and laryngeal cancers
may be largely explained by historical trends in tobacco
use. For other cancers however, the AFp is smaller, and
other factors such as alcohol [14], infections [15] and diet
[16] may also be important in determining trends in inci-
dence. Although smoking would undoubtedly contribute
to additional new cases, it would not be wise to ascribe
changes in incidence of these cancers primarily to
changes in tobacco use. This study is hence conﬁned to
cancer sites where at least 30% of the new cases are due
to cigarette smoking (AFp > 30%) based on the ﬁndings
of the EPIC study [6]. The eligible cancer sites (and cor-
responding ICD-10 codes) are: Oral cavity and Pharynx
(C00-14), Oesophagus (C15), Larynx (C32) and Lung,
bronchus, trachea (C33-34). An exception was made
for cancer of the lower urinary tract (C65-C68); while
up to half of the cases are attributed to smoking, we
excluded this site because diﬀerent and changing classiﬁ-
cation/coding practices [17] during the study period ren-
der international comparisons diﬃcult. Stomach and
colorectal cancer incidence are examined by Arnold
et al. [18].
We restricted this study to age group 35–74 to analyse
larger, more stable rates. Annual truncated age-stand-
ardised incidence rates (ASR) were calculated for each
country by sex, using the European standard population
[19]. To graphically summarise the trends, locally
weighted regression (Lowess) curves were ﬁtted to pro-
vide smoothed lines through the scatterplot of ASRs
by calendar period. A bandwidth of 0.3 was used, i.e.
30% of the data was used in smoothing each point,
except for female oesophageal and laryngeal trends,
where 50% of the data was used because of the random
ﬂuctuations inherent in the small numbers involved.
Rates are plotted on a log scale. Of note, for each can-
cer, the incidence scale is adapted to the range in inci-
dence across the continent and varies by sex.
Changes in incidence rates were quantiﬁed for age
groups 35–64, 65–74 and 35–74, for the 1998–2007 per-
iod (except Spain, for which 1996–2005 was used)
through average annual percentage change (AAPC)
and corresponding 95% conﬁdence intervals [C.I.] based
on the model from Clegg et al. [20]. AAPCs were esti-
mated using the Joinpoint Regression Program (version
3.5.3) from the Surveillance Research Program of the
US National Cancer Institute [21], and we used the
number of cases as the dependent variable, calendar
year as the independent variable, and the Poisson vari-
ance of the person-years at risk.
The proportions of adenocarcinomas (AdC) and
squamous cell carcinomas (SCC) among oesophageal
cancers for 1998–2002 were extracted from CI5 volume
IX [9].
To illustrate the association between smoking and
lung cancer incidence, and to further clarify the stage
of the smoking epidemic [22], we plotted the national
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1150 J. Lortet-Tieulent et al. / European Journal of Cancer 51 (2015) 1144–1163prevalence of daily smokers aged 15 and above and the
national or regional lung cancer incidence rates for ages
35 and above, for the maximum time period available in
EUREG and CI5plus databases (since 1955 for Den-
mark). The percentage of adult daily smokers was
extracted from the Organisation for Economic Co-oper-
ation and Development [23] and the World Health
Organization (WHO) [24] databases. In each of the four
regions, for illustrative purposes, we selected one coun-
try with a long series of smoking prevalence and lung
cancer incidence data.
3. Results
3.1. Lung cancer
Lung cancer incidence for men aged 35–74 diﬀered
markedly between countries, being highest in Belarus
(161 cases per 100,000 in 2007) and lowest in Sweden(40 cases per 100,000 in 2009), in the most recent period
(Fig. 1). In most European countries, rates for men have
decreased since the early 1990s, with the exception of
Norway, Finland, Spain and France, where rates have
remained broadly stable (Fig. 1). Over the 1998–2007
period, a signiﬁcant decline in lung cancer incidence
rates in men was observed in 14 of the 26 countries in
middle ages (35–64 years old) and 15 countries in older
ages (65–74 years old) (Figs. 2a and 2b and Appendix
Table 1). The declines were stronger in older men. In
the ﬁgure presenting the recent incidence rate versus
the 1998–2007 AAPC in middle-aged men (Fig. 2a),
the countries were clustered by region: in northern Euro-
pean countries (but Baltic countries), lung cancer inci-
dence rates were low and stable. Rates were
intermediate and declining in western European coun-
tries, and high and declining in central and eastern
European and Baltic countries. Rates in southern Euro-
pean countries did not have a uniform behaviour.
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Fig. 6. Trends in age-standardised (European) oral cavity and pharyngeal cancer incidence in men aged 35–74 by country and region, from 1988 to
the most recent year available (2005–2010). § Regional registries.
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incidence rates were observed in Iceland and Denmark,
with rates of 95 and 93 per 100,000 in 2010, respectively,
as well as in the Netherlands (71 cases per 100,000 in
2007). Denmark appears as having a higher rate than
Iceland in the graph (Fig. 3) due to smoothing. In the
same period, the lowest female rates were in Belarus
and Lithuania (13 cases per 100,000 in 2007). In contrast
to the decreasing trends observed in men, among women
rates of lung cancer by age group have increased over
time (Figs. 4a and 4b and Appendix Table 1), with the
notable exceptions of the declines in older Russian and
Lithuanian women in 1998–2007. Very recently (after
2005), early signs of stabilisation could be detected in
women aged 35–74 in central and eastern Europe, north-
ern Europe, Switzerland and Malta (Fig. 3). Fig. 4a(incidence rate versus AAPC in middle-aged women)
showed regional clusters of countries: moderate
increases in lung cancer incidence in northern countries
(but stable in Baltic countries and Iceland), upper high
and increasing incidence rates in western countries,
low to intermediate rates with strong increases in south-
ern Europe (but in Italy) and ﬁnally low to intermediate
rates in central and eastern Europe.
Due to the convergence of the trends by sex, the
male-to-female ratio has decreased during the last
20 years. Noticeably, in the most recent years (2006–
2008), the highest male (aged 35–64) rates were found
where the lowest female rates were: in central and east-
ern Europe, the Baltic countries and some southern
European countries. Conversely, the lowest male rates
and the highest female rates are found in northern
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ratio was closest to 1 in northern countries, with inci-
dence even higher in women than in men in Denmark,
Sweden and Iceland, among people aged 35–64 (Fig. 5).3.2. Oral cavity and pharyngeal cancer
Within Europe, incidence of cancers of the oral cavity
and pharynx among men in the most recent period var-
ied almost sixfold, from 12 (in Iceland in 2010) to 64 (in
Slovakia 2007) per 100,000 (Fig. 6). During the 1998–
2007 decade, rates among men were stable in most
countries in northern, western and central and eastern
Europe (Fig. 7 and Appendix Table 2). In southern
European countries (Croatia, Italy, Slovenia and Spain),
as well as in other countries (Russia, France, Estonia,
Switzerland and Poland), declines were consistently
observed. In the same period, rates in women were very
low in the former Soviet countries, e.g. in Belarus and
Lithuania (4 and 5 per 100,000 respectively, in 2007),
and were highest in western Europe, e.g. in Switzerland
(17 per 100,000 in 2008) (Fig. 8). In women, rates stabi-
lised or increased over the 1988–2007 period, with the
highest increase in the Czech Republic (average increase
of 6.4% per year, [95% C.I. 4.0; 8.9]) (Fig. 9 and by age
group in Appendix Table 2). While incidence rates were
higher in men compared to women throughout the study
period, as a consequence of the converging male and
female incidence trends, the male-to-female ratio hasdecreased during the last 20 years. In 2006–2008, this
ratio ranged from 12.6 in Belarus to 1.3 in Iceland.3.3. Laryngeal cancer
In the most recent period, incidence of cancer of the
larynx among men 35–74 was lowest in northern Euro-
pean countries (excluding the Baltic countries) and high-
est in central and eastern Europe, Baltic countries, Spain
and Croatia: rates ranged from 4 per 100,000 in Sweden
in 2009 to 30 per 100,000 in Bulgaria in 2008 (Fig. 10).
Rates tended to decline in most countries (Figs. 10
and 11, and by age group in Appendix Table 3), with
the greatest declines observed among men in Iceland
and Poland (Average Annual Percentage Change
(AAPC) of 13.7 [95% C.I. 23.3; 2.9] and 6.7
[8.8; 9.4], respectively). In women, the incidence rates
of laryngeal cancer were rather low, ranging from 0.5 to
2 per 100,000 in Belarus in 2007 and the Netherlands in
2008, respectively (Fig. 12). Although the patterns were
somewhat erratic due to the low number of cases, there
was a suggestion of an increase over the 1998–2007 dec-
ade in middle-aged women and a decrease at older ages
(Appendix Table 3). The ﬁgures presenting the recent
incidence versus AAPC (Fig. 11 and Appendix Fig. 1)
revealed regional clusters of countries (with Baltic coun-
tries included in the central and eastern European coun-
tries’ cluster, in men).3.4. Oesophageal cancer
The variation in recent incidence of oesophageal can-
cer among men was ﬁvefold, with incidence highest in the
Netherlands (24 per 100,000 in 2008) and lowest inMalta
(5 per 100,000 in 2009) (Fig. 13). Over the 1998–2007 per-
iod, in men aged 35–74, in general, countries in the
northern half of Europe have seen increases in oesopha-
geal cancer incidence (with the highest increase in the
Netherlands: AAPC of 3.5 [95% C.I. 2.8; 4.3]), while
countries in the southern half saw declines in incidence
(AAPC greater than 3.0 in France, Spain and Italy)
(Appendix Fig. 2). The increases were most pronounced
in middle-aged men (AAPCs of 4.4 in the Netherlands
[95% C.I. 3.1; 5.7], 4.2 in Norway [95% C.I. 0.7; 7.8],
and 4.1 in Finland [95% C.I. 0.6; 7.8] in men aged 35–
64 years) (Appendix Table 4). The male-to-female ratio
was higher for oesophageal cancer relative to other
smoking-related cancers in this study, ranging from 2.7
in Ireland to 20.8 in Belarus in 2006–2008. Because of
the random ﬂuctuations inherent in the small numbers
involved, it is diﬃcult to discern trends in women. How-
ever, incidence rates appeared to have increased over the
whole study period in most countries in western, central
and eastern Europe in women aged 35–74 (Fig. 14), with
the exception of a decline in Russia. Over the 1998–2007
period, in women, increases were signiﬁcant only in
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Fig. 8. Trends in age-standardised (European) oral cavity and pharyngeal cancer incidence in women aged 35–74 by country and region, from 1988
to the most recent year available (2005–2010). § Regional registries.
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(Appendix Fig. 3).
Table 2 presents the proportion of the two main his-
tological subtypes of oesophageal cancer, SCC and
AdC, by country and by sex, in 1998–2002. In men,
the majority of the cases were SCC. Less than 10% of
the cases were AdC in central and eastern Europe
(except in Czech Republic), the Baltic countries, Croatia
and Slovenia. In the other countries of northern Europe,
and in the Netherlands and Malta, AdC cases were more
frequent than SCC. In women, SCC always represented
the majority of the cases, except in Iceland and Latvia.
The highest proportions of SCC were found in Sweden,
Switzerland, Finland, France and Estonia, ranging from
73% to 82%.3.5. Temporal trend of cigarette smoking and lung cancer
incidence
National smoking prevalence (daily smokers aged 15
and above) and age-standardised lung cancer incidence
in adults (aged 35 and above) are plotted by sex in
Figs. 15a and 15b, for four selected countries, one in each
European region: Czech Republic (central and eastern
Europe), Denmark (northern Europe), Italy (southern
Europe) and France (western Europe). Although histor-
ically in those four countries the highest reported preva-
lence in Europe was as high as 70% (e.g. in Danish men
circa 1967), the highest current smoking prevalence was
29%, in French men. In men, the decline in smoking
prevalence was reﬂected in a later decline or stabilisation
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signiﬁcant AAPC (p 6 0.05); triangles indicate non-signiﬁcant AAPC.
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two- to three-decade lag time. In women, smoking prev-
alence has been increasing in France since the 1960s, but
remained stable in the Czech Republic since the
mid-1980s and in Italy since the 1980s. Conversely, prev-
alence has markedly declined over time in Denmark,
especially since the late 1990s, with current prevalence
of smokers at 20% among Danish women. In contrast
to the temporal trend in men, lung cancer incidence con-
tinued to increase in women in the Czech Republic, Italy
and France. The high incidence in Denmark (110 cases
per 100,000 in 2010) has stabilised very recently, four
decades after the peak of smoking prevalence.
4. Discussion
There remained large but changing variation in the
incidence rates of tobacco-related cancers. Generally,
male rates have been declining in lung, oral cavity and
pharyngeal and laryngeal cancers, while female rates
have been increasing in lung, oral cavity and pharyngeal
cancers. In lung and laryngeal cancers, rates were high-
est in central and eastern Europe, southern Europe and
the Baltic countries (in men). With respect to oesopha-
geal cancer, mixed trends emerged.
4.1. Lung cancer
These analyses reveal that the gap between male and
female lung cancer incidence is narrowing, particularlyin northern and western Europe, with lung cancer rates
in women aged 35–64 in 2006–2008 even higher than rates
in men in Denmark, Iceland and Sweden. This phenome-
non has also been observed in the Netherlands since the
mid-1990s in women <50 years old [25]. In southern Eur-
ope, declines in male incidence were also reported by
Znaor et al. in central Serbia over the 1999–2008 period
[26]. While the peak of lung cancer cases seems to have
been reached in men, as already reported by Malvezzi
et al. [27], our analyses indicate that it has not yet been
reached in women. It was estimated that, in Europe, in
2012, lung cancer—the majority of cases of which are
attributable to smoking—was the most commonly diag-
nosed cancer in 15 countries and the second most com-
mon cancer in 13 further countries in men, and ranked
second in three countries among women (Albania, Ice-
land and the UK). This neoplasm was estimated to be
the most frequent cause of death by cancer in men in all
European countries, with the exception of Sweden. In
women, lung cancer surpassed breast cancer mortality
in 12 of the 40 countries of the European region [7]. Con-
sequently, the pattern of the cancer burden in women in
Europe is approaching the cancer burden in men.
Tobacco certainly plays a major role (AFp of 82%), but
occupational exposure (such as asbestos [28]) and envi-
ronmental exposures also account for a small proportion
of the lung cancer cases, possibly explaining some of the
observed between-country diﬀerences in rates.4.2. Oral cavity and pharyngeal cancers
Although oral cavity and pharyngeal cancers are
strongly related to smoking – with a cumulative risk
among lifelong male smokers around 16 times higher
than in never smokers – [29] the trends in oral cavity
and pharyngeal cancers diﬀer noticeably from those of
lung cancer. In particular, male rates have been increas-
ing or remained stable in some countries while lung can-
cer incidence rates have declined (e.g. Czech Republic,
Denmark, the UK and the Netherlands). This suggests
that other detrimental risk factors, such as alcohol [14]
and human papillomavirus (HPV) [15] may substantially
modify the trends. Conversely, diets rich in fruit and veg-
etables may prevent upper aerodigestive tract cancers
[30]. For oral cavity cancer, the population attributable
risk is 22% for tobacco alone and 40% for tobacco in
combination with alcohol [14]. According to the WHO,
alcohol consumption has been increasing in Czech
Republic and Denmark from around 9 L of pure alcohol
per year per person aged 15+ to 15 L and from 7 L to 11,
respectively, over the 1960–2010 period [24]. This may
partly explain the increase in the number of new oral
and pharyngeal cancer patients. Conversely, the highest
levels of consumption in Europe used to be around
25 L in France, 18 L in Italy, 14 L in Spain at the begin-
ning of the 1960’s, but 12, 6 and 10 L respectively in 2010
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Fig. 10. Trends in age-standardised (European) laryngeal cancer incidence in men aged 35–74 by country and region, from 1988 to the most recent
year available (2005–2010). § Regional registries.
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is associated with an increased risk of about ﬁvefold for
oral and pharyngeal cancer [31], the decrease in average
consumption may partly explain the decline in the num-
ber of new cases in those countries among men – who, on
average, drink more than women. However, even lower
doses of alcohol consumption (i.e. 61 drink/day)
increase the risk of cancer by about 20% [31]. In Europe,
around year 2000, the proportion of people abstaining
from drinking alcohol for the past 12 months was, on
average in each country, 18% among men and 32%
among women [24], putting the rest of the population
at increased risk of cancer due to alcohol consumption.
The AFp for HPV varies by sub-site and also by
European region. In the oropharynx, including tonsiland base of tongue, it has been estimated to range from
17% in southern Europe to 38–39% in northern, western
and eastern Europe [15]. Oropharyngeal cancer inci-
dence signiﬁcantly increased among men, and at youn-
ger ages, over the 1983–2002 period, in the
Netherlands, Slovakia, Denmark and the UK, thereby
increasing the total number of new oral cavity and pha-
ryngeal cancer cases. On the contrary, oropharyngeal
cancer incidence declined in France and Italy [32].
4.3. Laryngeal cancer
Tobacco and alcohol are the main drivers behind the
trends of laryngeal cancer incidence. They have a
synergistic eﬀect on this cancer [33]. In the ARCAGE
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2007 (except 1996–2005 for Spain) and age-standardised (European)
incidence rates (ASR) of the most recent year of laryngeal cancer in
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digestive tract cancers, the risk estimate of hypopharyn-
geal/laryngeal cancer for tobacco alone was 6.7 and 1.0
for alcohol alone. However, joint exposure to tobacco
and alcohol triggered an odd of 14.5 [14]. The eﬀect of
alcohol on laryngeal cancer also diﬀers by sub-site, i.e.
cancer of the supraglottis is more strongly related to
alcohol consumption compared to the glottis/subglottis
[34]. Finally, occupational exposures [35] may also have
an impact on the incidence, and explain country-level
diﬀerences.4.4. Oesophageal cancer
In men, while lung cancer incidence is declining,
oesophageal cancer incidence is increasing in a number
of countries, particularly in the Netherlands, Finland,
Belarus, Germany and the UK (ages 35–74). The diﬀer-
ence in the observed trends for lung cancer (a proxy for
past smoking behaviours) and oesophageal cancer is
probably explained in part by diﬀering risk factors for
the two main subtypes of oesophageal cancer: more dis-
tantly located adenocarcinomas (AdC) and more proxi-
mal squamous cell carcinomas (SCC). They have
diﬀerent aetiologies. Tobacco has a stronger association
with SCC, whereas gastro-oesophageal reﬂux disease,
presence of abdominal fat and Barrett oesophagus
markedly increase the risk of AdC of the oesophagus
[36]. In our study, the proportion of AdC in men (35–
74 years old) was highest in the Netherlands, Ireland,the UK and Nordic countries (Table 2). Hence, in those
countries, the observed increasing oesophageal cancer
trends are likely to be mainly driven by risk factors other
than smoking. A global assessment by Edgren et al. of
the oesophageal AdC epidemic showed that it started
between the 1960s (the UK) and the 1990s (Scandina-
via), with considerable magnitude in variation between
cancer registries [37]. Other local factors such as con-
sumption of hot tea may also explain the marked diﬀer-
ences for the high UK rates in both sexes [38]. As for
SCC, alcohol further modiﬁes the risk related to tobacco
smoking [14]. Heavy alcohol consumption (i.e.
P4 drinks/day) increases the risk of oesophageal SCC
about ﬁvefold and lower (i.e. 61 drink/day) doses of
alcohol consumption by about 30% [31]. As in oral cav-
ity and pharyngeal cancers, the important decline in the
average alcohol consumption in some countries (e.g.
France, Spain and Italy) may already have had a posi-
tive impact and could partly explain the marked
decrease in incidence of oesophageal cancers in men in
these countries.4.5. Temporal trends in cigarette smoking and lung cancer
Recently, Thun et al. have modiﬁed the four stages
of the “tobacco epidemic” [22] to accommodate gender
diﬀerences [39]. Some of the variations in smoking
prevalence between countries can be explained by dif-
ferences in economic development. Today, on the one
hand, in most European countries, men have reached
the ﬁnal stage, which involves falling smoking rates
[40] and widening socioeconomic diﬀerences in smok-
ing [41]. On the other hand, women are at contrasting
stages within the epidemic continuum. In most of
northern Europe, the tobacco epidemic in women
seems to have reached the fourth stage, whereas France
still lags behind and is only at the second stage, char-
acterised by an increase in both smoking prevalence
[2] and lung cancer. We also observed longer lag times
between the peak of smoking prevalence and lung can-
cer incidence than previously reported in the USA and
Japan (40 versus 15–30 years) [42]. This could be due
to diﬀerences in smoking behaviour and pattern, ciga-
rette type, other carcinogenic exposures and suscepti-
bility to lung cancer between countries.
The ﬁgures presenting the recent incidence rates ver-
sus the AAPC during 1998–2007 revealed regional clus-
tering, most notably for lung and laryngeal cancers. We
observed closer relationship within regions with the cur-
rent burden (recent incidence rate) than with the trend
(AAPC). We can infer that the today’s burden in those
cancer sites is the result of past regional inﬂuence, while
what will happen in the future (estimated by the recent
AAPC) is determined at the country level.
Some limitations of this study are worth mention-
ing. Firstly, seven countries had no national registration
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Fig. 12. Trends in age-standardised (European) laryngeal cancer incidence in women aged 35–74 by country and region, from 1988 to the most
recent year available (2005–2010). § Regional registries.
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tries to obtain a proxy of the national incidence. Still,
for four countries (France, Italy, Spain and Poland)
the population coverage was still less than 10%. In our
analyses, we hence assumed that the cancer incidence
in the rest of the population was equivalent to that in
the areas covered by the regional registries. This may
(or may not) be a reasonable assumption depending
on whether the populations covered by the regional reg-
istries are representative of the national population, par-
ticularly in terms of smoking patterns. Secondly,
although we chose cancer registries that had passed
the most rigorous selection process of CI5 publication,
data quality may have changed over time. In particular,there may have been improvements in completeness in
some registries [43]. Thirdly, in an eﬀort to standardise
our analysis across countries, we assessed the changes
in rates over the 1998–2007 period. As such, this method
fails to capture very recent changes (after 2005), e.g. in
lung cancer in women. Finally, we grouped countries
by geographical region according to the United Nation
(UN) classiﬁcation, yet heterogeneity exists within
region. For example, the rates and trends in Baltic coun-
tries (Latvia, Estonia and Lithuania) resemble more clo-
sely those of the former communist states of central and
eastern Europe (including Poland, Slovakia, Russian
Federation, Bulgaria, Belarus and the Czech Republic)
than those of the other countries of northwestern
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Fig. 13. Trends in age-standardised (European) oesophageal cancer incidence in men aged 35–74 by country and region, from 1988 to the most
recent year available (2005–2010). § Regional registries.
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styles. Likewise, incidence trends in the Netherlands,
classiﬁed as being in western Europe, more closely
resemble those of the UK, Ireland and Denmark.
5. Conclusions
Our study illustrates the impact of the economic con-
ditions as well as successes and failures of tobacco con-
trol policies in Europe. These policies have contributed
to decreasing smoking prevalence in men, but have failed
thus far to prevent smoking initiation in women or to
support them in quitting smoking. Implementation was
far too late in central and eastern Europe and the Balticcountries. Tobacco control remains a top priority for
cancer control in Europe [44]; advances in cancer therapy
have not had much success in improving survival for the
cancers in this study [45,46]. Key targets for prevention
eﬀorts should include men in central and eastern Europe
[27], southern Europe and Baltic countries and young
women across Europe [7]. In recognition of the heteroge-
neity and diversity between populations, targeted and
adaptable approaches to cancer prevention are essential
[47]. As the EUREG database is continuously updated
with new incidence, mortality and survival data and
new population-based cancer registries, it oﬀers enor-
mous opportunities to increase the knowledge on cancer
and its control in the years to come.
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Fig. 14. Trends in age-standardised (European) oesophageal cancer incidence in women aged 35–74 by country and region, from 1988 to the most
recent year available (2005–2010). § Regional registries.
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Table 2
Proportion of oesophageal cancer by main histological sub-type, by sex, in 1998–2002, ages 35–74. Source: Cancer Incidence in Five Continents
Vol. IX [9].
Region Country Men Women
Squamous cell carcinoma (%) Adenocarcinoma (%) Squamous cell carcinoma (%) Adenocarcinoma (%)
Central & eastern Europe
Belarus 66 9 43 18
Bulgaria – – – –
Czech Republic 56 23 55 18
Polanda – – – –
Russian Federation 55 8 51 9
Slovakia 70 9 55 26
Northern Europe
Denmark 43 44 65 25
Estonia 82 5 82 0
Finland 52 37 75 19
Iceland 34 63 22 44
Ireland 34 54 64 24
Latvia 63 9 31 17
Lithuania 63 8 63 12
Norway 50 42 66 26
Sweden 46 47 73 23
United Kingdoma 25 59 55 27
Southern Europe
Croatia 56 6 50 12
Italya 66 18 68 13
Malta 36 43 60 20
Slovenia 77 9 63 22
Spaina 74 17 63 18
Western Europe
Austria 54 25 50 18
Francea 77 17 81 11
Germanya 61 17 64 14
Switzerlanda 62 31 74 17
The Netherlands 36 56 58 33
Proportions in Bulgaria and Poland are not displayed due to the low proportion of microscopically veriﬁed cases (35% in men and 27% in women in
Bulgaria, 57% and 43% in Poland Cracow and 77% and 74% in Kielce respectively). The other histological subtypes not displayed are: other
speciﬁed carcinoma, Unspeciﬁed carcinoma, sarcoma, other speciﬁed morphology and unspeciﬁed morphology.
a Regional registries: France (Doubs, Herault, Isere, Haut-Rhin, Somme, Tarn); Germany (Brandenburg, Hamburg, Saxony, Mecklenburg,
North Rhine-Westphalia, Saarland); Poland (Kielce, Cracow); Italy (Modena, Parma, Ragusa, Romagna, Torino, Varese); Spain (Granada,
Murcia, Navarra, Tarragona); Switzerland (Geneva, St Gall-Appenzell), United Kingdom (England and Scotland).
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fellner); Belarus – Belarusian Cancer Registry (Prof
Okeanov); Bulgaria – Bulgarian National Cancer Regis-
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trict Cancer Registry (Dr. Rachtan), Kielce Regional
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Fig. 15a. Age-standardised (European) lung cancer incidence rates per
100,000 in men aged 35 and above and prevalence of daily smokers in
men aged 15 and above in Czech Republic, Denmark, Italy and
France.
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Fig. 15b. Age-standardised (European) lung cancer incidence rates per
100,000 in women aged 35 and above and prevalence of daily smokers
in women aged 15 and above in Czech Republic, Denmark, Italy and
France.
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tional Cancer Registry (Dr. Safaei Diba, Dr. Kaiser-
ova); Slovenia – Cancer Registry of Republic of
Slovenia (Prof Primic Zˇakelj); Spain – Granada Cancer
Registry (Dr. Sanchez-Perez), Murcia Cancer Registry
(Dr. Navarro Sa´nchez), Navarra Cancer Registry (Dr.
Ardanaz Aicua), Tarragona Cancer Registry (Prof
Peris-Bonet, Dr. Galceran); Sweden – Swedish Cancer
Registry (Ms Klint, Dr. Heyman); Switzerland – Geneva
Cancer Registry (Prof Bouchardy), St. Gallen-Appenzell
Cancer Registry (Prof Kuehni, Dr. Ess), The Nether-
lands – The Netherlands Cancer Registry, Comprehen-
sive Cancer Centre South (Dr. De Ridder-Sluiker);
United Kingdom – Eastern England, Northern and
Yorkshire Cancer Registry, North West Cancer Intelli-
gence Service, Oxford Cancer Intelligence Unit, South
West Cancer Registry (Mr David Meecham, Dr. Gill
Lawrence, Dr. Stiller); Russian Federation – Russian
Centre for technologic information and epidemiological
studies in the ﬁeld of oncology.
Appendix A. Supplementary data
Supplementary data associated with this article can
be found, in the online version, at http://dx.doi.org/
10.1016/j.ejca.2013.10.014.References
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